Observed Signal · Nov 3, 2026 · earnings · Source: SEC API · Impact: 4.1/5
10-Q Financial Filing Analysis for CGI (2026-11-03)
Corcept Therapeutics reported significant financial growth for Q3 2026, driven by expanding commercial execution across its endocrinology franchise and the initial launch ramp of Lifyorli (relacorilant). Net product revenue rose 64.0% year-over-year to $340.5M, supported by $249.1M in hypercortisolism product sales and a $91.4M contribution from Lifyorli following its April 2026 U.S. launch. Operating income surged tenfold to $114.7M from $10.2M in Q3 2025, benefiting from gross margin expansion (cost of sales at just 1.4% of revenue) and disciplined operating expenditure leverage. Net income reached $126.8M, bolstered by a $6.5M net income tax benefit. Corcept maintains a robust balance sheet with $662.3M in cash and marketable securities and no long-term debt, positioning the company securely as it awaits the PDUFA target review date of December 17, 2026, for relacorilant in hypercortisolism.
Demonstrates rapid commercial adoption and revenue diversification via the launch of Lifyorli alongside robust profitability and cash accumulation ahead of a pivotal PDUFA regulatory decision in December 2026.
Track CGI Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Q3 2026 net product revenue grew 64.0% year-over-year to $340.47M, with newly approved oncology drug Lifyorli contributing $91.41M and hypercortisolism products generating $249.07M.
- Operating income for the quarter reached $114.72M compared to $10.22M in Q3 2025, while diluted earnings per common share expanded to $1.01 compared to $0.16.
- The resubmitted New Drug Application (NDA) for relacorilant in endogenous hypercortisolism has an assigned PDUFA target action date of December 17, 2026.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
10-Q Financial Filing Analysis for CGI (2026-07-29)
Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.
8-K Financial Filing Analysis for CGI (2026-11-03)
On November 3, 2026, Corcept Therapeutics Incorporated furnished a Form 8-K under Items 2.02 and 7.01 announcing the release of its financial results for the third quarter ended September 30, 2026, along with a corporate update. The detailed financial statements and operational metrics were provided via an accompanying press release attached as Exhibit 99.1. The filing fulfills regulatory disclosure requirements under Regulation FD without formal incorporation into Securities Act registration statements.
Core Lab Reports Q3 2026 Results: Revenue $132.1M
Core Laboratories Inc. reported third quarter 2026 revenue of $132.1 million, up 6% sequentially but down 2% year-over-year. Operating income was $12.1 million (ex-items: $12.6 million). GAAP EPS was $0.12, while EPS ex-items was $0.16. The company generated $1.7 million in free cash flow, repurchased 87,873 shares for $1.1 million, and declared a Q4 2026 dividend. Revenue growth was driven by international demand across both segments, particularly Reservoir Description and Production Enhancement, despite ongoing geopolitical disruptions. Core Lab anticipates flat Q4 revenue due to Middle East conflicts but expects growth in 2027.
Receive all future signals for CGI & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.